Subscribe to Tribune Pulse
View Past Issues

TTS 2024 By-Election Results for Vice President

We would like to congratulate Gabriel Gondolesi (Argentina) for being elected as Vice President. Gabriel will start his two-year term at the conclusion of the TTS 2024 Congress. We would like to thank all the candidates for running and all our members who voted in the by-election.
See Full Election Results

Gabriel Gondolesi

Argentina
Biography

Gabriel Gondolesi, Argentina

Prof. Gabriel E. Gondolesi, MD, MAAC, FACS, was born in Tandil on 6/11/1968. Graduated from UNLP. Surgical Resident in La Plata. Fellow in Liver Transplantation (LT) at the Favaloro Foundation - FF (1997-1999), and in Multiorgan Transplantation at Mount Sinai Hospital in New York (1999-2001). Associate Professor in LT and Chief of Intestinal Transplantation (2001-2005). In 2006, he returned to FF; performed the first adult and pediatric intestinal transplants, the first Hepato-Pulmonary transplant, and the first LT with LD for colon cancer metastasis successfully in Argentina; the first Liver-Intestinal transplant, the first Domino + Split LT in LatAm, and the first LT with grafts from two living donors (LD) in the Americas. Health Researcher at CONICET. Author of 160 publications, director of 7 theses. Doctor Honoris Causa from the Universidad San Francisco Javier de Chuquisaca (2012). Received 20 national and international awards. Served as Chairman of the 2015 ISBTS and CO-Chairman of TTS2022, Past-President of IRTA, Senior treasurer of TTS, Member of the WHO Donation and Transplantation Working Group. Winner of the Konex Award in Surgery 2023.

Click for details

TTS 2024 Update

Don't miss out on this unique opportunity to learn, share, and connect with the global transplantation community. See you at TTS 2024!

New Workshops!

TTS-Vitallink: Strengthening deceased organ transplantation capacity in LMICs

Wednesday, Sept 25 - 08:00

  • Curie Ahn, Korea 
    How to build a deceased organ transplantation team in LMICs?
  • Dr. Katayoun Najafizadeh, Iran 
    How can hospital infrastructure for deceased organ transplantation be established in LMICs?
  • Dr. Chloe Ballesté Delpierre, Spain 
    Establishing a system for deceased organ transplantation in LMICs: Strategies and considerations
  • Masumbuko Mwashambwa, Tanzania, United Republic of 
    Panel discussion: Critical issues law and regulations
  • Alejandro Nino-Murcia, Colombia 
    Panel discussion: Critical issues access for Venezuelan refugees
See details

Religious perspectives regarding the ethical issues associated with clinical xenotransplantation

Sunday Sept 22, 2024 - 13:30

  • Don Renzo Pegoraro, Italy 
    Panelist (Roman Catholic)
  • Syed Shabih Haider Zaidi, United Kingdom 
    Panelist (Shia Islam)
  • Tarek Elgawhary, Italy 
    Panelist (Sunni Islam)
  • Joris Gielen, United States 
    Panelist (Hinduism)
  • Komal Kashyap, India 
    Panelist (Hinduism)
  • Samuel Brown, United States 
    Panelist (Church of Jesus Christ of Latter-day Saints)
  • Terri Laws, United States 
    Panelist (African-American religious studies)
See details
Registration Details
Congress Website
View Program
View Speakers

Upcoming Webinar Presentations

Click here for details and to register
Click here for details and to register
Click here for details and to register

Transplantation Journal Highlights

Transplantation - Social Media Content

Low-dose Interleukin-2 Therapy: Fine-tuning Treg in Solid Organ Transplantation?
Regulatory T cells (Treg), a subset of CD4+ T cells, are potent regulators of immune reactions, which have been shown to be a promising therapeutic alternative to toxic immunosuppressive drugs. Data support the utility of Treg in managing immunopathologies, including solid organ transplant rejection, graft-versus-host disease, and autoimmune disorders. Notably, reports suggest that interleukin-2 (IL-2) is critical to survival of Treg, which constitutively express high levels of CD25, that is, the IL-2 receptor α-chain, and are exquisitely sensitive to IL-2, even at very low concentrations in contrast to effector T cells, which only upregulate IL-2 receptor α-chain on activation.
Read More
Banff 2022 Kidney Commentary: Reflections and Future Directions
In September 2022, in Banff, Alberta, Canada, the XVIth Banff meeting, corresponding to the 30th anniversary of the Banff classification, was held, leading to 2 recent publications. Discussions at the Banff meeting focused on proposing improvements to the Banff process as a whole. In line with this, a unique opportunity was offered to a selected group of 16 representatives from the pathology and transplant nephrology community, experts in the field of kidney transplantation, to review these 2 Banff manuscripts.
Read More
View Video

Transplantation Direct - Social Media Content

Surgical Complications Following Renal Transplantation in a Large Institutional Cohort
Successful renal transplantation (RTx) relies on immunosuppression and an optimal surgical course with few surgical complications. Studies reporting the postoperative complications after RTx are heterogeneous and often lack systematic reporting of complications. This study aims to describe and identify postoperative short-term and long-term complications after RTx in a large institutional cohort and identify risk factors for a complicated surgical course.
Read More
Expanding Access to High KDPI Kidney Transplant for Recipients Aged 60 y and Older: Cost Utility and Survival
Modern organ allocation systems are tasked with equitably maximizing the utility of transplanted organs. Increasing the use of deceased donor organs at risk of discard may be a cost-effective strategy to improve overall transplant benefit. We determined the survival implications and cost utility of increasing the use of marginal kidneys in an older adult Canadian population of patients with end-stage kidney disease.
Read More

In Case You Missed It…Recent Recordings

Click here to view recording
Click here to view recording
Click here to view recording
Click here to view recording

In the News 

ASHI Research Grants

American Society for Histocompatibility & Immunigenetics Scientific Awards

ASHI has three scientific awards to recognize and financially support early-career investigators, innovation scholars, and research. Learn more about each award including eligibility, project scope, and application details and deadlines.

APPLICATION DEADLINE: AUGUST 1, 2024

EARLY CAREER INVESTIGATOR AWARD

The aim of the Early Career Investigator Award (ECIA) is to support future research leaders who are committed to conducting impactful basic or translational science research. This program offers ASHI members an award of up to $40,000 for research related to histocompatibility or immunogenetics in various disciplines such transplantation, cancer, autoimmunity, infectious disease, disease association, or pharmacogenomics.
Learn more

INNOVATION SCHOLARSHIP AWARDS

The goal of the Innovation Scholarship Award is to recognize and further a significant body of work in the fields of HLA, immunogenetics and/or transplant immunology as demonstrated by publications, educational initiatives and/or developed translational tools and analyses. Each of three recipients will receive a $1500 honorarium. These awards will be presented in the ASHI annual meeting when distinguished candidates are identified.
Learn more

MICHAEL SCHMIEDERER RESEARCH SUPPORT AWARD

The aim of the Michael Schmiederer Research Support Award (MSRSA) is to support impactful clinical research in the fields of histocompatibility and immunogenetics. This program offers an ASHI member a $15,000 one-year grant for research related to various clinical disciplines such as transplantation, cancer, autoimmunity, infectious disease, disease association, or pharmacogenomics. The award is sponsored by Labcorp in memory of a beloved coworker, Michael Schmiederer, PhD, S(ACHI).
Learn more
Click here to visit the ASHI Scientific Awards Page for complete details

Upcoming Meetings and Announcements 

Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada

Info

Privacy Policy
Terms of Use
Copyright Notice